Canaccord Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)

Canaccord analyst Gary Newman reiterated a Buy rating and $300.00 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ).

The analyst commented: "The second interim topline OS result from the HERIZON-GEA-01 Phase 3 demonstrated that Ziihera plus chemotherapy had a statistically significant and clinically meaningful OS benefit vs. trastuzumab plus chemotherapy in 1L GEA. This follows last week's approval of Ziihera in combination with tislelizumab and chemo (HER2+ IHC 3+ and IHC 2+/ISH+) and Ziihera plus chemo alone (HER2+ IHC 3+) for 1L GEA. Notably, the primary distinction between the two interim analyses (first was announced 11/17/25) is that in this latest one it met the study's remaining primary endpoint looking at the doublet arm (Ziihera plus chemo), whereas in the first only the triplet arm (Ziihera plus tislelizumab and chemo) had reached the threshold for definitive superiority in OS, with the Ziihera doublet showing only a strong trend toward statistical significance at that earlier timepoint. With longer follow-up in the second interim analysis, the OS HR for both Ziihera containing regimens improved, reinforcing durable outcomes and establishing a clear advantage over the current SOC across both regimens. Alongside these results, JAZZ has submitted the updated OS data to be presented at a major medical meeting in 4Q26 and will also submit this data to global health agencies. Notably, last week JAZZ updated its peak sales guidance for Ziihera to $3-5B, up from the prior >$2B range, and the confirmed OS benefit in both the doublet and triplet arms for 1L GEA is supportive of that. We reiterate our BUY on JAZZ with the recent approval for Ziihera in 1L GEA an important step forward towards improving the mix to oncology; see our recently initiated coverage of JAZZ."

For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.

Shares of Jazz Pharmaceuticals closed at $250.68 yesterday.

You May Also Be Interested In

• Kepler Cheuvreux Upgrades Entain PLC (ENT:LN) (GMVHF) to Buy
• Bernstein SocGen Group Reiterates Outperform Rating on SLB (SLB)
• Oddity Tech Ltd (ODD) PT Raised to $16 at Truist Securities